Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rhea-AI Summary
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in an upcoming investor conference.
Management will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 11:20 am ET. The virtual event will be accessible via webcast on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 12 Alerts
On the day this news was published, RAPP gained 2.41%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $27M to the company's valuation, bringing the market cap to $1.16B at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference.
TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – fireside chat on Wednesday, September 17, 2025, at 11:20 am ET.
Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When is Rapport Therapeutics (RAPP) presenting at TD Cowen's Neuropsychiatry Summit?
How can investors access Rapport Therapeutics' (RAPP) presentation at the TD Cowen Summit?
What type of medicines does Rapport Therapeutics (RAPP) develop?
Is Rapport Therapeutics' (RAPP) presentation at TD Cowen's Summit in-person or virtual?
